Revisiting Ehlers-Danlos Syndrome as a Relative Contraindication to Elective Plastic Surgery: A Retrospective Matched Cohort Study
Abstract
BACKGROUND
Ehlers-Danlos Syndromes comprise a heterogeneous group of connective tissue disorders, often associated with concerns about poor wound healing and elevated surgical complication rates. This study evaluated the safety of elective plastic surgery in EDS patients relative to matched controls. We hypothesized that EDS patients would not experience higher complication rates relative to matched controls.
METHODS
An IRB approved retrospective cohort study of EDS patients and matched controls who underwent elective plastic surgery between 2003 and 2023 was conducted at a tertiary health care system. Patients were matched for comorbidities, medications, and other factors affecting wound healing. Complication rates, categorized by severity and timing, were compared between groups. Data analysis included paired t-tests and McNemar's tests. To detect a complication rate difference of 10% (α=0.05, β=0.2), a sample of 97 patients per group was required.
RESULTS
One-hundred EDS patients (86% female, mean age 43.29±17.45 years, mean BMI 26.47±6.01) and 100 matched controls (86% female, mean age 42.98±18.12 years, mean BMI 26.82±6.61) were included. The most common EDS subtype was hypermobile EDS (41%), followed by classical (6%) and vascular EDS (2%). Complications were observed in 25% of EDS patients and 35% of controls (p=0.16). There was no significant difference in the rate of minor complications (EDS: 19% vs. Controls: 24%, p=0.39) or major complications (EDS: 6% vs.…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 97 participants or records.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.